X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TVT-004, a conjugate of the endocannabinoid anandamide with potential to treat a broad range of neurologic disorders, and additional programs with a range of neuro-inflammation and neuro-oncology applications.
Lead Product(s): TVT-004
Therapeutic Area: Neurology Product Name: TVT-004
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
The proceeds from the Series A financing will be used to support Travecta's growth and advance the development of TVT-004, Travecta's lead non-opioid product targeting pain.
Lead Product(s): TVT-004
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: TKS1
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
